Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051004 | 0.89 | CXCR4 (0.80) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2504776 | 0.87 | CXCR4 (0.86) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2511995 | 0.87 | CXCR4 (0.71) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4759519 | 0.86 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2513440 | 0.86 | CXCR4 (0.79) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Bromide SCHEMBL30096616 | 0.86 | CXCR4 (0.98) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL13909512 | 0.85 | CXCR4 (0.91) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2513424 | 0.85 | CXCR4 (0.86) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3259860 | 0.85 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL30096605 | 0.85 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.